Mesoamerican Nephropathy (MeN): What We Know so Far

被引:23
|
作者
Sanchez Polo, Vicente [1 ]
Garcia-Trabanino, Ramon [2 ,3 ]
Rodriguez, Guillermo [4 ]
Madero, Magdalena [5 ]
机构
[1] Inst Guatemalteco Seguridad Social, Guatemala City, Guatemala
[2] Ctr Hemodialisis, San Salvador, El Salvador
[3] Fondo Social Emergencia Salud, Tierra Blanca, El Salvador
[4] Hosp Dr RA Calderon Guardia, Serv Nephrol, Caja Costarricense Seguro Social, San Jose, Costa Rica
[5] Inst Nacl Cardiol Ignacio Chavez, Div Nephrol, Juan Badiano 1,Col Secc 16, Mexico City 14080, DF, Mexico
关键词
Mesoamerican nephropathy; MeN; heat stress; CKDu; CKDnt; endemic nephropathy; regional nephropathy; CHRONIC KIDNEY-DISEASE; AGRICULTURAL COMMUNITIES; INTERNATIONAL SOCIETY; UNKNOWN ETIOLOGY; CENTRAL-AMERICA; HEAT-STRESS; DEHYDRATION; RISK; DISPARITIES; MORTALITY;
D O I
10.2147/IJNRD.S270709
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
In 2002, a report from El Salvador described a high incidence of chronic kidney disease (CKD) of unknown cause, mostly in young males from specific coastal areas. Similar situations were observed along the Pacific Ocean coastline of other Central American countries and southern Mexico (Mesoamerica). This new form of CKD has been denominated Mesoamerican endemic nephropathy (MeN). The typical presentation of MeN is a young male from an endemic area with a family history of CKD, low eGFR, high serum creatinine, low level of albuminuria, hypokalemia, hyperuricemia, and urine urate crystals. Kidney biopsy demonstrating tubulointerstitial nephritis remains the gold standard for diagnosis but is available only for a minority. Commonly proposed causes include thermal stress/dehydration and/or exposure to environmental pollutants. However, likely, a third factor, which could be genetic or epigenetic, could contribute to the cause and development of the disease, along with social determinants. Currently, preventive measures focus on minimizing workers exposure to thermal stress/dehydration. There are many research opportunities and priorities should include clinical trials to evaluate the efficacy and safety of the current treatment protocols, along with etiological and genetic studies, and the development of kidney disease data systems. Although there is scant and controversial literature with regard s to the etiology, diagnosis and management of the disease, our aim is to provide the reader a vision of the disease based on our experience.
引用
收藏
页码:261 / 272
页数:12
相关论文
共 50 条
  • [21] Update on omicron variant: What we know so far
    Choudhary, Gajendra
    Prajapat, Manisha
    Kumaravel, J.
    Prabha, Praisy K.
    Sarma, Phulen
    Handa, Vrishbhanu
    Kaur, Harminder
    Patel, Ajay Prakash
    Medhi, Bikash
    INDIAN JOURNAL OF PHARMACOLOGY, 2022, 54 (01) : 41 - 45
  • [22] Scalp Seborrheic Dermatitis: What We Know So Far
    Leroy, Anne Kelly
    de Almeida, Rita Fernanda Cortez
    Obadia, Daniel Lago
    Frattini, Sidney
    Melo, Daniel Fernandes
    SKIN APPENDAGE DISORDERS, 2023, 9 (03) : 160 - 164
  • [23] HIV and neoplasms: What do we know so far?
    de Souza, Thais Faria
    Sym, Yasmin Vianna
    Chehter, Ethel Zimberg
    EINSTEIN-SAO PAULO, 2023, 21 : eRW0231
  • [24] Neuroproteomics in Epilepsy: What Do We Know so Far?
    do Canto, Amanda M.
    Donatti, Amanda
    Geraldis, Jaqueline C.
    Godoi, Alexandre B.
    da Rosa, Douglas C.
    Lopes-Cendes, Iscia
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2021, 13
  • [25] Strongly Quasiconvex Functions: What We Know (So Far)
    Sorin-Mihai Grad
    Felipe Lara
    Raúl T. Marcavillaca
    Journal of Optimization Theory and Applications, 2025, 205 (2)
  • [26] TAVI in nonagenarians, what do we know so far?
    Diez-Villanueva, Pablo
    Rivero, Fernando
    REC-INTERVENTIONAL CARDIOLOGY, 2021, 3 (04): : 245 - 246
  • [27] China coronavirus: what do we know so far?
    Mahase, Elisabeth
    BMJ-BRITISH MEDICAL JOURNAL, 2020, 368 : m308
  • [28] Refractory hypertension: what do we know so far?
    Muxfeldt, Elizabeth Silaid
    Chedier, Bernardo
    JOURNAL OF HUMAN HYPERTENSION, 2021, 35 (03) : 181 - 183
  • [29] Trends in HeartMate 3: What we know so far
    Lanfear, Allison T.
    Hamandi, Mohanad
    Fan, Joy
    DiMaio, J. Michael
    George, Timothy J.
    JOURNAL OF CARDIAC SURGERY, 2020, 35 (01) : 180 - 187
  • [30] Diet in the Treatment of Epilepsy: What We Know So Far
    Verrotti, Alberto
    Iapadre, Giulia
    Di Francesco, Ludovica
    Zagaroli, Luca
    Farello, Giovanni
    NUTRIENTS, 2020, 12 (09) : 1 - 19